Scroll

nefopam 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1891	13669-70-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nefopam fenazoxine (+/-)-Nefopam nefopam hydrochloride nefopam HCl	Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26) Molecular weight: 253.35 Formula: C17H19NO CLOGP: 2.91 LIPINSKI: 0 HAC: 2 HDO: 0 TPSA: 12.47 ALOGS: -3.50 ROTB: 1

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nefopam
fenazoxine
(+/-)-Nefopam
nefopam hydrochloride
nefopam HCl

Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26)

Molecular weight: 253.35
Formula: C17H19NO
CLOGP: 2.91
LIPINSKI: 0
HAC: 2
HDO: 0
TPSA: 12.47
ALOGS: -3.50
ROTB: 1

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	34 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	3 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	1.04 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	36 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	5.60 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	12 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	5 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1978	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	335.03	26.84	115	4919	26399	56260634
Cholestasis	329.46	26.84	114	4920	26799	56260234
Hepatic cytolysis	113.42	26.84	41	4993	10865	56276168
Acute kidney injury	108.67	26.84	120	4914	240643	56046390
Drug reaction with eosinophilia and systemic symptoms	98.69	26.84	50	4984	30254	56256779
Acute generalised exanthematous pustulosis	91.14	26.84	34	5000	9835	56277198
Thrombocytopenia	72.07	26.84	74	4960	136150	56150883
Coma	71.96	26.84	52	4982	59603	56227430
Foetal megacystis	70.43	26.84	10	5024	26	56287007
Pancreatitis acute	69.02	26.84	37	4997	25087	56261946
Drug dependence	67.04	26.84	35	4999	22498	56264535
Tonic clonic movements	63.31	26.84	16	5018	1254	56285779
Fatigue	58.50	26.84	3	5031	788549	55498484
Peripheral nerve injury	57.54	26.84	12	5022	398	56286635
Anticholinergic syndrome	56.64	26.84	16	5018	1918	56285115
Mixed liver injury	49.26	26.84	17	5017	3927	56283106
Shock haemorrhagic	48.27	26.84	21	5013	9012	56278021
Miosis	47.61	26.84	19	5015	6573	56280460
Spinal epidural haemorrhage	45.63	26.84	8	5026	102	56286931
Hyperkalaemia	41.06	26.84	35	4999	50830	56236203
Cell death	41.02	26.84	13	5021	2306	56284727
Encephalopathy	40.76	26.84	30	5004	35295	56251738
Epidural haemorrhage	38.04	26.84	7	5027	119	56286914
Eosinophilia	37.50	26.84	23	5011	20054	56266979
Metabolic acidosis	37.15	26.84	30	5004	40424	56246609
Urinary bladder rupture	36.91	26.84	7	5027	141	56286892
Hyperlactacidaemia	35.63	26.84	12	5022	2576	56284457
Granulomatous liver disease	35.24	26.84	9	5025	735	56286298
Cutaneous T-cell lymphoma	34.12	26.84	10	5024	1365	56285668
Pancreatic pseudoaneurysm	34.11	26.84	6	5028	78	56286955
Foetal heart rate abnormal	33.01	26.84	8	5026	527	56286506
Agranulocytosis	32.53	26.84	22	5012	22637	56264396
Stevens-Johnson syndrome	32.53	26.84	22	5012	22641	56264392
Drug ineffective	31.55	26.84	22	5012	918967	55368066
Naevus haemorrhage	31.54	26.84	6	5028	123	56286910
Poisoning deliberate	31.14	26.84	16	5018	9937	56277096
Blood phosphorus decreased	30.54	26.84	12	5022	3985	56283048
Prescription drug used without a prescription	30.53	26.84	10	5024	1970	56285063
Somnolence	30.04	26.84	53	4981	163360	56123673
Myoclonus	29.89	26.84	18	5016	15185	56271848
Porphyria	29.78	26.84	6	5028	167	56286866
Epidural analgesia	29.45	26.84	5	5029	52	56286981
Livedo reticularis	29.34	26.84	10	5024	2225	56284808
Autonomic nervous system imbalance	27.88	26.84	10	5024	2583	56284450

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Agranulocytosis	147.57	29.25	64	3604	21183	31672493
Hepatocellular injury	137.00	29.25	61	3607	21483	31672193
Rash maculo-papular	126.67	29.25	61	3607	25658	31668018
Cholestasis	119.04	29.25	58	3610	25017	31668659
Drug reaction with eosinophilia and systemic symptoms	117.73	29.25	61	3607	29957	31663719
Eosinophilia	84.69	29.25	45	3623	23208	31670468
Alveolar lung disease	84.23	29.25	17	3651	366	31693310
Pulmonary interstitial emphysema syndrome	80.61	29.25	17	3651	457	31693219
Confusional state	74.42	29.25	84	3584	133250	31560426
Hyperleukocytosis	63.23	29.25	18	3650	1711	31691965
Diffuse alveolar damage	59.62	29.25	18	3650	2101	31691575
Pancytopenia	55.54	29.25	59	3609	87257	31606419
Acute kidney injury	54.07	29.25	107	3561	279607	31414069
Urethral valves	53.03	29.25	11	3657	272	31693404
Mixed liver injury	49.59	29.25	16	3652	2321	31691355
Eosinophilic pneumonia	49.01	29.25	17	3651	3080	31690596
Hyperammonaemia	48.50	29.25	20	3648	5813	31687863
Oesophageal achalasia	44.81	29.25	10	3658	352	31693324
Haemolytic anaemia	41.49	29.25	21	3647	9775	31683901
Consciousness fluctuating	38.09	29.25	11	3657	1100	31692576
Toxic skin eruption	37.86	29.25	20	3648	10160	31683516
Generalised oedema	35.58	29.25	20	3648	11481	31682195
Hepatitis	34.66	29.25	25	3643	22041	31671635
Hepatic encephalopathy	32.37	29.25	20	3648	13651	31680025
Pancreatitis acute	31.35	29.25	25	3643	25575	31668101
Thrombocytopenia	30.34	29.25	57	3611	142690	31550986
Eczema	30.17	29.25	20	3648	15397	31678279

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	433.63	22.33	176	8668	45915	70873685
Cholestasis	406.87	22.33	170	8674	47702	70871898
Drug reaction with eosinophilia and systemic symptoms	199.96	22.33	111	8733	57902	70861698
Agranulocytosis	157.96	22.33	84	8760	40214	70879386
Acute kidney injury	137.60	22.33	226	8618	474398	70445202
Rash maculo-papular	122.31	22.33	77	8767	50468	70869132
Hepatic cytolysis	119.96	22.33	55	8789	19137	70900463
Eosinophilia	114.37	22.33	68	8776	40251	70879349
Acute generalised exanthematous pustulosis	98.97	22.33	45	8799	15352	70904248
Pancreatitis acute	92.46	22.33	62	8782	45162	70874438
Mixed liver injury	91.46	22.33	33	8811	6216	70913384
Thrombocytopenia	90.34	22.33	129	8715	238981	70680619
Confusional state	80.15	22.33	134	8710	284264	70635336
Pulmonary interstitial emphysema syndrome	79.47	22.33	17	8827	453	70919147
Alveolar lung disease	76.62	22.33	17	8827	539	70919061
Fatigue	74.87	22.33	8	8836	824311	70095289
Coma	73.89	22.33	73	8771	91771	70827829
Tonic clonic movements	63.35	22.33	19	8825	2008	70917592
Drug dependence	59.59	22.33	44	8800	37277	70882323
Hyperleukocytosis	57.59	22.33	18	8826	2183	70917417
Toxic skin eruption	57.12	22.33	34	8810	20128	70899472
Hepatitis	56.32	22.33	48	8796	49932	70869668
Encephalopathy	53.29	22.33	51	8793	61610	70857990
Pancytopenia	50.43	22.33	77	8767	151030	70768570
Diffuse alveolar damage	50.11	22.33	18	8826	3345	70916255
Peripheral nerve injury	47.65	22.33	12	8832	661	70918939
Haemolytic anaemia	46.74	22.33	28	8816	16766	70902834
Anticholinergic syndrome	44.59	22.33	16	8828	2964	70916636
Febrile bone marrow aplasia	44.14	22.33	24	8820	11967	70907633
Miosis	43.15	22.33	25	8819	14076	70905524
Drug ineffective	42.77	22.33	33	8811	939719	69979881
Neutropenia	40.47	22.33	95	8749	257061	70662539
Eosinophilic pneumonia	40.15	22.33	17	8827	4888	70914712
Hyperammonaemia	39	22.33	21	8823	10272	70909328
Oesophageal achalasia	37.21	22.33	10	8834	711	70918889
Hyperthermia	36.82	22.33	24	8820	16647	70902953
Anaphylactic shock	36.18	22.33	31	8813	32459	70887141
Foetal heart rate abnormal	35.86	22.33	8	8836	260	70919340
Cell death	35.86	22.33	15	8829	4185	70915415
Hyperbilirubinaemia	34.66	22.33	26	8818	22542	70897058
Spinal epidural haemorrhage	34.31	22.33	7	8837	147	70919453
Poisoning deliberate	33.91	22.33	23	8821	17037	70902563
Gamma-glutamyltransferase increased	33.00	22.33	36	8808	50649	70868951
Consciousness fluctuating	32.19	22.33	11	8833	1765	70917835
Pancreatic pseudoaneurysm	32.12	22.33	6	8838	78	70919522
Epidural haemorrhage	31.76	22.33	7	8837	215	70919385
Prothrombin time ratio decreased	31.73	22.33	9	8835	782	70918818
Myoclonus	31.09	22.33	26	8818	26329	70893271
Pneumonia	30.99	22.33	18	8826	596214	70323386
Hepatic encephalopathy	30.71	22.33	24	8820	22094	70897506
Shock haemorrhagic	30.37	22.33	22	8822	18084	70901516
Urinary retention	30.26	22.33	35	8809	52485	70867115
Hyperlactacidaemia	30.00	22.33	14	8830	5058	70914542
Transaminases increased	29.93	22.33	33	8811	46985	70872615
Naevus haemorrhage	29.55	22.33	6	8838	123	70919477
Generalised oedema	28.94	22.33	23	8821	21685	70897915
Metabolic acidosis	27.81	22.33	40	8804	74306	70845294
Epidural analgesia	27.62	22.33	5	8839	54	70919546
Hallucination	27.03	22.33	40	8804	76220	70843380
Hallucinations, mixed	26.99	22.33	14	8830	6348	70913252
Porphyria	26.58	22.33	6	8838	206	70919394
Hallucination, visual	24.83	22.33	24	8820	29313	70890287
Cutaneous T-cell lymphoma	24.80	22.33	10	8834	2543	70917057
Blood phosphorus decreased	24.73	22.33	13	8831	6056	70913544
Granulomatous liver disease	23.78	22.33	8	8836	1224	70918376
Symmetrical drug-related intertriginous and flexural exanthema	23.70	22.33	7	8837	701	70918899
Target skin lesion	23.56	22.33	5	8839	128	70919472
Hepatitis acute	23.49	22.33	17	8827	13945	70905655
Prescription drug used without a prescription	23.25	22.33	10	8834	2987	70916613
Respiratory gas exchange disorder	23.14	22.33	7	8837	761	70918839
Dizziness	22.73	22.33	15	8829	464126	70455474
Renal failure	22.59	22.33	63	8781	189007	70730593
Stevens-Johnson syndrome	22.50	22.33	25	8819	35882	70883718

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N02BG06	NERVOUS SYSTEM ANALGESICS OTHER ANALGESICS AND ANTIPYRETICS Other analgesics and antipyretics
MeSH PA	D000700	Analgesics
MeSH PA	D018712	Analgesics, Non-Narcotic
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D018373	Peripheral Nervous System Agents
MeSH PA	D018689	Sensory System Agents
CHEBI has role	CHEBI:35640	adrenergic uptake inhibitors
CHEBI has role	CHEBI:50949	SSRI
CHEBI has role	CHEBI:51039	dopamine reuptake inhibitor

Drug Use | Suggest Off label Use Form| |View source of the data|

None

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.85	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Type	Activity value (-log[M])	Bioact source
Sodium channel protein type 5 subunit alpha	Ion channel	Q14524	SCN5A_HUMAN			WOMBAT-PK
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	Ki	7.54	PDSP
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	Ki	7.48	PDSP
5-hydroxytryptamine receptor 2A	GPCR	P28223	5HT2A_HUMAN	Ki	5.77	PDSP
5-hydroxytryptamine receptor 2B	GPCR	P41595	5HT2B_HUMAN	Ki	6.48	PDSP
5-hydroxytryptamine receptor 2C	GPCR	P28335	5HT2C_HUMAN	Ki	7.25	PDSP
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN	Ki	6.28	PDSP

External reference:

ID	Source
N0000167217	NUI
D05133	KEGG_DRUG
C0027556	UMLSCUI
CHEBI:88316	CHEBI
CHEMBL465026	ChEMBL_ID
DB12293	DRUGBANK_ID
D009340	MESH_DESCRIPTOR_UI
4450	PUBCHEM_CID
3018	INN_ID
23327-57-3	SECONDARY_CAS_RN
4UP8060B7J	UNII
4324	RXNORM
001582	NDDF
004636	NDDF
322300008	SNOMEDCT_US
350324006	SNOMEDCT_US
419768004	SNOMEDCT_US
CHEMBL1407915	ChEMBL_ID

Pharmaceutical products:

None